Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Different Antioxidative and Antiapoptotic Effects of Piceatannol and Resveratrol. | Academic Article |
Why?
|
| Resveratrol as a nontoxic excipient stabilizes insulin in a bioactive hexameric form. | Academic Article |
Why?
|
| Resveratrol: Friend or Foe? | Academic Article |
Why?
|
| Antiadipogenic Effects and Mechanisms of Combinations of Genistein, Epigallocatechin-3-Gallate, and/or Resveratrol in Preadipocytes. | Academic Article |
Why?
|
| Resveratrol, a SIRT1 activator, attenuates aging-associated alterations in skeletal muscle and heart in mice. | Academic Article |
Why?
|
| Resveratrol: is selectivity opening the key to therapeutic effects? | Academic Article |
Why?
|
| Anti-Acanthamoebic properties of resveratrol and demethoxycurcumin. | Academic Article |
Why?
|
| Resveratrol up-regulates AMPA receptor expression via AMP-activated protein kinase-mediated protein translation. | Academic Article |
Why?
|
| Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells. | Academic Article |
Why?
|
| Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. | Academic Article |
Why?
|
| Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application. | Academic Article |
Why?
|
| Blood Pressure-Lowering by the Antioxidant Resveratrol Is Counterintuitively Mediated by Oxidation of cGMP-Dependent Protein Kinase. | Academic Article |
Why?
|
| Response by Prysyazhna et al to Letter Regarding Article, "Blood Pressure-Lowering by the Antioxidant Resveratrol Is Counterintuitively Mediated by Oxidation of cGMP-Dependent Protein Kinase". | Academic Article |
Why?
|
| An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. | Academic Article |
Why?
|
| Effects of Resveratrol on Crosstalk between Canonical ?-Catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients with Metabolic Syndrome: A Case Control Study. | Academic Article |
Why?
|